Evaluation of Mcl-1 Inhibitors in Preclinical Models of Multiple Myeloma

被引：2
|
作者：
Belmonte, Matthew A. [1 ]
Adam, Ammar [1 ]
Borrelli, Deanna [1 ]
Bhavsar, Deepa [1 ]
Bebernitz, Christina [1 ]
Hird, Alexander [1 ]
Secrist, Paul [1 ]
机构：
[1] AstraZeneca, Waltham, MA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3428.3428
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Changes in Mcl-1 and Bim expression with bortezomib and melphalan therapy for multiple myeloma.
    Popat, R
    Goff, L
    Oaekervee, HE
    Cavenagh, JD
    Joel, SP
    BLOOD, 2005, 106 (11) : 697A - 697A
  • [42] BRAF/MEK inhibitors selectively prime melanoma for Mcl-1 dependence and sensitize to Mcl-1 inhibition
    Kump, Karson J.
    Miao, Lei
    Ansari, Nurul
    Lombard, David B.
    Nikolovska-Coleska, Zaneta
    CANCER RESEARCH, 2019, 79 (13)
  • [43] Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bc1-xL inhibitors
    Li, Rongshi
    Cheng, Chunwei
    Balasis, Maria E.
    Liu, Yan
    Garner, Thomas P.
    Daniel, Kenyon G.
    Li, Jerry
    Qin, Yong
    Gavathiotis, Evripidis
    Sebti, Said M.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 90 : 315 - 331
  • [44] Substituted indole Mcl-1 inhibitors: a patent evaluation (WO2015148854A1)
    Song, Ting
    Wang, Ziqian
    Zhang, Zhichao
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2016, 26 (11) : 1227 - 1238
  • [45] Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors
    Liang, Xiao
    Li, Xue
    Zhao, Zhiyuan
    Nie, Yiming
    Yao, Zefu
    Ren, Wandi
    Yang, Xinying
    Hou, Xuben
    Fang, Hao
    BIOORGANIC CHEMISTRY, 2022, 121
  • [46] Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis
    Gomez-Bougie, Patricia
    Halliez, Maxime
    Moreau, Philippe
    Pellat-Deceunynck, Catherine
    Amiot, Martine
    CANCER LETTERS, 2016, 383 (02) : 204 - 211
  • [47] Deciphering molecular specificity in MCL-1/BAK interaction and its implications for designing potent MCL-1 inhibitors
    Wei, Hudie
    Wang, Haolan
    Xiang, Shuang
    Wang, Jiaqi
    Qu, Lingzhi
    Chen, Xiaojuan
    Guo, Ming
    Lu, Xiaoyun
    Chen, Yongheng
    CELL DEATH AND DIFFERENTIATION, 2025,
  • [48] Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma
    Gupta, Vikas A.
    Matulis, Shannon M.
    Conage-Pough, Jason E.
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Boise, Lawrence H.
    BLOOD, 2017, 129 (14) : 1969 - 1979
  • [49] Schedule dependent effect of bortezomib and melphalan for multiple myeloma associated with changes in Mcl-1 expression
    Popat, R
    Goff, L
    Oakervee, H
    Cavenagh, JD
    Joel, SP
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 99 - 99
  • [50] Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
    De Veirman, Kim
    Van Ginderachter, Jo A.
    Lub, Susanne
    De Beule, Nathan
    Thielemans, Kris
    Bautmans, Ivan
    Oyajobi, Babatunde O.
    De Bruyne, Elke
    Menu, Eline
    Lemaire, Miguel
    Van Riet, Ivan
    Vanderkerken, Karin
    Van Valckenborgh, Els
    ONCOTARGET, 2015, 6 (12) : 10532 - 10547
12345